Strides Pharma Science Approves Strategic Investment in Pivot Path, Selling Majority Stake

Strides Pharma Science Approves Strategic Investment in Pivot Path, Selling Majority Stake​

Strides Pharma Science Limited has approved a strategic transaction involving the sale of a majority stake in its subsidiary, Pivot Path Private Limited. The deal brings in Ascent Capital and Vintage Classic as investors, while Ascent Capital also provides primary infusion capital into Pivot Path to fuel its expansion.

The Board of Directors of Strides Pharma Science Limited approved the strategic investment during a meeting held on June 27, 2026. Upon completion of the transaction, Pivot Path will be reclassified as an Associate Company.

Transaction Details and Investment Overview​

The proposed transaction comprises two main elements: the sale of a majority stake in Pivot Path by Strides and a primary capital infusion into the company.

Strides Pharma Science Limited plans to divest its majority share in Pivot Path for an aggregate consideration of approximately Rs. 1,000 million. This payment will be structured in two tranches: Rs. 750 million payable at the initial closing, with the remaining Rs. 250 million due on the first anniversary of the closing date.

Concurrently, Ascent Capital Advisors India Private Limited intends to infuse Rs. 500 million into Pivot Path to accelerate its growth phase.

Ascent Growth Trust (acting through Ascent Capital) and Vintage Classic Limited are set to be the investors in this transaction. Neither investor group is associated with the Promoter or Promoter Group of Strides Pharma Science Limited.

Business Context and Performance​

Pivot Path Private Limited originated within Arco Lab Private Limited, which served as a Global Capability Centre (GCC) for Strides, developing expertise across life sciences consulting, digital transformation, quality, compliance, and technology-enabled operational services. As demand from external pharmaceutical and life sciences companies grew, the business was carved out into Pivot Path via a Scheme of Arrangement approved by the Hon'ble National Company Law Tribunal in May 2026.

The transaction has been based on an independent valuation conducted by a SEBI registered merchant banker, which reflected Pivot Path's differentiated capabilities, long-term growth potential, and established customer relationships. The company confirmed that the proposed transaction does not constitute a related party transaction.

The financial contributions of Pivot Path to Strides for the fiscal year 2025-26, on a post-demerger basis, are detailed below:

Timeline and Capital Structure​

The definitive agreements for the sale are slated for execution before June 30, 2026. The completion of the share sale is expected by June 30, 2026. Meanwhile, the primary infusion by Ascent into Pivot Path is scheduled to be completed by July 31, 2026.

Following the successful completion of the transaction, the resultant capital structure of Pivot Path will be as follows:

STAR Stock Price Movement​

Shares of Strides Pharma Science Limited slipped by 3.26% on Thursday, settling at ₹1082.2 after falling ₹36.20 from the previous close. The stock saw a traded volume of 183,992 shares during the day.